Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05161195 · ClinicalTrials.gov registry record · Phase 4
Roll-over Study to Allow Continued Access to Ribociclib
A Phase 4 study of Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals.
- Active
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
- 20
- Study locations
NCT05161195: Active Phase 4 study of Metastatic Breast Cancer, sponsored by Novartis Pharmaceuticals.
NCT05161195 is a Phase 4 study of Metastatic Breast Cancer that is active but no longer recruiting, run by Novartis Pharmaceuticals. The registered enrollment target is 134 participants, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 18 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05161195, a Phase 4 study of Metastatic Breast Cancer, is active but no longer recruiting, sponsored by Novartis Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a Novartis-sponsored global study that has reached its primary objective(s).
Primary Outcome
The percentage of participants with treatment-emergent adverse events will be summarized, including significant adverse events leading to discontinuation, and adverse events leading to dose adjustment
Conditions Studied
Interventions
- DRUG Tamoxifen
- DRUG Anastrozole
- DRUG Letrozole
- DRUG Goserelin
- DRUG Ribociclib
Study Locations (20)
Georgia
- Summit Cancer Care - Savannah
- John D Archbold Memorial Hospital - Thomasville
New Jersey
- Englewood Health - Englewood
- The Valley Hospital-Luckow Pavillion - Paramus
Arizona
- Ironwood Cancer and Research Centers - Chandler
Arkansas
- Highlands Oncology Group - Fayetteville
California
- Beverly Hills Cancer Center - Beverly Hills
Colorado
- Poudre Valley Hospital - Fort Collins
Florida
- Mid Florida Hematology And Onc Ctr - Orange
Illinois
- Duly Health and Care - Plainfield
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2022-07-07 |
| Est. Completion | 2030-08-14 |
| Phase | Phase 4 |
What the registry record for NCT05161195 still lists
NCT05161195 is an interventional study that assigns participants to a tested intervention. The registered 134 participants enrollment target is mid-sized for trials with a published cap, below the 204-participant average among 139 other Metastatic Breast Cancer trials with a reported enrollment target (34% lower).
The record links to 1 condition, with Metastatic Breast Cancer appearing as the primary indexed condition, and to 5 interventions - of which Tamoxifen is the first listed.
NCT05161195 names 20 study sites across 18 states, led by Georgia, New Jersey, Arizona.
Frequently Asked Questions
What is clinical trial NCT05161195 about?
NCT05161195 is a clinical study titled "Roll-over Study to Allow Continued Access to Ribociclib". The purpose of this study is to assess the long-term safety of ribociclib (LEE011) in combination with other drugs and provide post-trial access (PTA) to participants who are currently receiving treatment with ribociclib in combination with other drugs and continuing to have clinical benefit in a No...
What is the current status of trial NCT05161195?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2022-07-07. Estimated completion is 2030-08-14.
What conditions does trial NCT05161195 study?
This clinical trial studies the following conditions: Metastatic Breast Cancer.
What interventions are being tested in trial NCT05161195?
The interventions under investigation include: Tamoxifen (DRUG), Anastrozole (DRUG), Letrozole (DRUG), Goserelin (DRUG), Ribociclib (DRUG).
Who is sponsoring clinical trial NCT05161195?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05161195 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05161195's enrollment target sits among peer trials
134 46th of 139 higher than 94 of 139 other Metastatic Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer
RECRUITING · Phase 1
-
Nurturing Exercise Routine for Greater Improvement in Zest and Energy on Enhertu
RECRUITING · Phase 2
-
Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC
RECRUITING · Phase 2
-
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
RECRUITING · Phase 2
-
BettER: Biomarker Driven Early Therapeutic Selection in Patients With HR+ HER2- Metastatic or Unresectable Breast Cancer
RECRUITING · NA
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02469662 · 134 participants · NA
Clinical Outcomes Study of the Nexel Total Elbow
- NCT03110822 · 134 participants · Phase 1
A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients
- NCT04678648 · 134 participants · Phase 1
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
- NCT05264857 · 134 participants · NA
Decision Aid and Thyroid Nodules Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI